Bio-Bridge Science, a vaccine development company, has signed a joint venture agreement with JR Scientific Inc., a California maker of classical and custom cell culture medium and sera products. The JV will produce cell culture medium in a Beijing facility. The new JV will be capitalized with 10 million RMB ($1.5 million). Bio-Bridge Science will contribute 5.1 million RMB for a 51% share of the JV; JRS will provide technology in return for a 15% stake; and other investors will add the remaining capital. More details...
Stock Symbol: (OTCBB: BGES)
Sorry... this feature or article is only available to subscribers.